REAL-WORLD EXPERIENCE WITH ZANUBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKAEMIA – PATIENT PROFILE, TREATMENT PATTERNS, AND SAFETY: PRELIMINARY ANALYSIS OF FRENCH ROZALY STUDY
EHA Library, Florian Bouclet,
4209449
A GLOBAL MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 3 REGISTRATIONAL STUDY OF LISAFTOCLAX (APG-2575) IN PREVIOUSLY TREATED CLL/SLL: GLORA TRIAL IN PROGRESS
EHA Library, Matthew Davids,
4209467
BGB-16673 VERSUS IDELALISIB + RITUXIMAB (R), BENDAMUSTINE + R, OR VENETOCLAX + R RE-TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: THE PHASE 3 CADANCE-302 TRIAL
EHA Library, Paolo Ghia,
4209476
PATIENT CHARACTERISTICS, GENETIC PROFILING, AND TREATMENT PATTERNS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN LITHUANIA, 2021–2024
EHA Library, Regina Pileckyte,
4209495
A STUDY OF BEXOBRUTIDEG (NX-5948), A BTK DEGRADER, IN PATIENTS WITH CLL/SLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR, A NON-COVALENT BTK INHIBITOR AND A BCL2 INHIBITOR: DAYBREAK CLL-201
EHA Library, Dima El-Sharkawi,
4209501
ROCKET-CLL: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY OF ROCBRUTINIB (LP-168) VERSUS PIRTOBRUTINIB IN COVALENT BTK INHIBITOR (CBTKI) PRETREATED RELAPSED OR REFRACTORY (R/R) CLL/SLL
EHA Library, Yu Chen,
4209515